Drug Profile
ORG 26576
Alternative Names: ORG26576Latest Information Update: 17 Mar 2010
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Developer Merck & Co
- Class Isoxazoles
- Mechanism of Action AMPA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder
Most Recent Events
- 20 Jun 2008 Phase-I/II clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
- 20 Jun 2008 Phase-I/II clinical trials in Depression in USA (PO)
- 19 Nov 2007 Organon has been acquired and merged into Schering-Plough